MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis
NASDAQ:MIRM • US6047491013
105.89 USD
+0.73 (+0.69%)
At close: Feb 23, 2026
105.89 USD
0 (0%)
After Hours: 2/23/2026, 8:01:00 PM
Overall MIRM gets a fundamental rating of 4 out of 10. We evaluated MIRM against 521 industry peers in the Biotechnology industry. MIRM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MIRM is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- MIRM had negative earnings in the past year.
- MIRM had a positive operating cash flow in the past year.
- In the past 5 years MIRM always reported negative net income.
- MIRM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -5.30%, MIRM belongs to the top of the industry, outperforming 86.18% of the companies in the same industry.
- With an excellent Return On Equity value of -14.26%, MIRM belongs to the best of the industry, outperforming 86.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 79.92%, MIRM belongs to the top of the industry, outperforming 85.41% of the companies in the same industry.
- In the last couple of years the Gross Margin of MIRM has declined.
- The Profit Margin and Operating Margin are not available for MIRM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, MIRM has more shares outstanding
- MIRM has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for MIRM has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 6.47 indicates that MIRM is not in any danger for bankruptcy at the moment.
- MIRM's Altman-Z score of 6.47 is fine compared to the rest of the industry. MIRM outperforms 75.43% of its industry peers.
- MIRM has a debt to FCF ratio of 6.97. This is a slightly negative value and a sign of low solvency as MIRM would need 6.97 years to pay back of all of its debts.
- The Debt to FCF ratio of MIRM (6.97) is better than 91.17% of its industry peers.
- MIRM has a Debt/Equity ratio of 1.06. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 1.06, MIRM is doing worse than 75.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Altman-Z | 6.47 |
ROIC/WACCN/A
WACC8.43%
2.3 Liquidity
- MIRM has a Current Ratio of 3.31. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
- MIRM has a Current ratio of 3.31. This is in the lower half of the industry: MIRM underperforms 60.65% of its industry peers.
- A Quick Ratio of 3.16 indicates that MIRM has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.16, MIRM is doing worse than 60.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 |
3. Growth
3.1 Past
- MIRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.43%, which is quite impressive.
- MIRM shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.66%.
- The Revenue has been growing by 160.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
3.2 Future
- MIRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.74% yearly.
- Based on estimates for the next years, MIRM will show a very strong growth in Revenue. The Revenue will grow by 25.40% on average per year.
EPS Next Y85%
EPS Next 2Y39.15%
EPS Next 3Y31.86%
EPS Next 5Y31.74%
Revenue Next Year53.97%
Revenue Next 2Y38.16%
Revenue Next 3Y31.77%
Revenue Next 5Y25.4%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MIRM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 90.98% of the companies in the same industry are more expensive than MIRM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 123.24 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MIRM's earnings are expected to grow with 31.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.15%
EPS Next 3Y31.86%
5. Dividend
5.1 Amount
- No dividends for MIRM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
105.89
+0.73 (+0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners99.71%
Inst Owner Change5.21%
Ins Owners1.66%
Ins Owner Change0.51%
Market Cap5.47B
Revenue(TTM)471.79M
Net Income(TTM)-41.63M
Analysts86.25
Price Target116.99 (10.48%)
Short Float %18.17%
Short Ratio9.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.86%
Min EPS beat(2)63.96%
Max EPS beat(2)129.77%
EPS beat(4)3
Avg EPS beat(4)26.25%
Min EPS beat(4)-99.42%
Max EPS beat(4)129.77%
EPS beat(8)4
Avg EPS beat(8)-5.65%
EPS beat(12)7
Avg EPS beat(12)-12.67%
EPS beat(16)10
Avg EPS beat(16)-42.14%
Revenue beat(2)2
Avg Revenue beat(2)8.03%
Min Revenue beat(2)0.25%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)7.03%
Min Revenue beat(4)0.25%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)4.34%
Revenue beat(12)11
Avg Revenue beat(12)8.01%
Revenue beat(16)13
Avg Revenue beat(16)3.12%
PT rev (1m)10.5%
PT rev (3m)39.88%
EPS NQ rev (1m)759.01%
EPS NQ rev (3m)152.04%
EPS NY rev (1m)14.73%
EPS NY rev (3m)60.13%
Revenue NQ rev (1m)1.16%
Revenue NQ rev (3m)3.32%
Revenue NY rev (1m)0.6%
Revenue NY rev (3m)1.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.6 | ||
| P/FCF | 123.24 | ||
| P/OCF | 122.26 | ||
| P/B | 18.74 | ||
| P/tB | 90.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)0.86
FCFY0.81%
OCF(TTM)0.87
OCFY0.82%
SpS9.13
BVpS5.65
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.3% | ||
| ROE | -14.26% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.92% | ||
| FCFM | 9.41% |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | 6.97 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.46% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.31 | ||
| Quick Ratio | 3.16 | ||
| Altman-Z | 6.47 |
F-Score6
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y85%
EPS Next 2Y39.15%
EPS Next 3Y31.86%
EPS Next 5Y31.74%
Revenue 1Y (TTM)53.66%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
Revenue Next Year53.97%
Revenue Next 2Y38.16%
Revenue Next 3Y31.77%
Revenue Next 5Y25.4%
EBIT growth 1Y56.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.22%
EBIT Next 3Y33.68%
EBIT Next 5YN/A
FCF growth 1Y142.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y150.52%
OCF growth 3YN/A
OCF growth 5YN/A
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the fundamental rating for MIRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to MIRM.
What is the valuation status for MIRM stock?
ChartMill assigns a valuation rating of 2 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.
Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.
Can you provide the expected EPS growth for MIRM stock?
The Earnings per Share (EPS) of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 85% in the next year.